EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Neoadjuvant anlotinib for locally advanced thyroid cancer: a single-arm phase II study (ALTER-T001)

Dapeng Li, Ankui Yang, Zhaohui Wang, Minghua Ge, Xiangqian Zheng, Songfeng Wei, Jianwu Qin, Shengying Wang, Youben Fan, Shuwei Chen, Yibo Chen, Naisi Huang und 5 weitere

Frontiers in Endocrinology · 02.11.2026 · 17

DOI: 10.3389/fendo.2026.1960030 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Frontiers in Endocrinology, online erschienen am 02.11.2026. Verfasst von Dapeng Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Neck Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Cli…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Indoles, Neoadjuvant Therapy, Quinolines. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Locally advanced thyroid cancer involving critical cervical structures is often not amenable to upfront surgery, and effective strategies are needed to improve surgical feasibility. ALTER-T001 study evaluated the safety, efficacy, and quality of life (QoL) of neoadjuvant anlotinib in this setting.

Methods

Patients with pathologically confirmed, locally advanced thyroid cancer not amenable to surgery received neoadjuvant anlotinib. “Not amenable to surgery” tumors included those unresectable, high-risk for surgery/recurrence, severely impairing QoL upon resection, or with limited adhesion to blood vessels, esophagus, or trachea. Primary endpoint was objective response rate (ORR). Secondary endpoints included time to response (TTR), disease control rate (DCR), actual operation rate, R0 resection rate, progression-free survival (PFS), QoL, and safety.

Results

In 50 DTC patients, ORR and DCR were 42.0% and 84.0% (48.8% and 97.7% in 43 evaluable cases). Median TTR was 2.8 months. Surgery occurred in 21 (42.0%) patients, yielding a 57.1% R0 rate. Median PFS in non-surgical patients was 29.8 months. The most frequent grade ≥3 treatment-related adverse event (TRAE) was hypertension (18.0%). TRAEs led to dose reductions and interruptions in 8 (16.0%) and 5 (10.0%) patients, respectively. No treatment-related deaths occurred. Global health status remained generally stable during early treatment, although deterioration in several function domains was observed. One MTC patient achieved R0 resection after 4 cycles and is presented separately as a descriptive case.

Conclusion

Neoadjuvant anlotinib exhibited acceptable efficacy, tolerability, and QoL profiles in locally advanced DTC not amenable to surgery, with potential to reduce tumor burden and facilitate conversion surgery. Larger MTC cohorts are needed to further evaluate the efficacy and safety of neoadjuvant anlotinib. Clinical Trial Registration https://www.chictr.org.cn/ , identifier ChiCTR2100048077.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsIndolesNeoadjuvant TherapyQuinolinesThyroid NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

anlotiniblocally advanced thyroid cancerneoadjuvant treatmentphase IIquality of life

Substanzen

anlotinibAntineoplastic AgentsIndolesQuinolines

Autor:innen und Institutionen

  • Department of Thyroid and Neck Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer In…
  • Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology…
  • Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
  • Department of Thyroid & Head and Neck Surgery, Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital, Zhengzhou, China.
  • Department of Head-Neck Surgery, Anhui Provincial Cancer Hospital, Hefei, China.

Zitieren

APA

Li, D., Yang, A., Wang, Z., Ge, M., Zheng, X., Wei, S., Qin, J., Wang, S., Fan, Y., Chen, S., Chen, Y., Huang, N., Tan, Z., Zhou, B., Wang, S., Wang, Y., & Gao, M. (2026). Neoadjuvant anlotinib for locally advanced thyroid cancer: a single-arm phase II study (ALTER-T001). Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1960030

Vancouver

Li D, Yang A, Wang Z, Ge M, Zheng X, Wei S, et al. Neoadjuvant anlotinib for locally advanced thyroid cancer: a single-arm phase II study (ALTER-T001). Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1960030

BibTeX
@article{Li2026,
  author = {Li, Dapeng and Yang, Ankui and Wang, Zhaohui and Ge, Minghua and Zheng, Xiangqian and Wei, Songfeng and Qin, Jianwu and Wang, Shengying and Fan, Youben and Chen, Shuwei and Chen, Yibo and Huang, Naisi and Tan, Zhuo and Zhou, Bin and Wang, Shoujun and Wang, Yu and Gao, Ming},
  title = {Neoadjuvant anlotinib for locally advanced thyroid cancer: a single-arm phase II study (ALTER-T001)},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1960030}
}
Kostenlos starten →